Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial

Luis Rivera, Rasmus S Pedersen, Lourdes Peña, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Pernille I Nielsen, Charlotte Sørensen, Jes Dietrich, Ananda S Bandyopadhyay, Birgit Thierry-Carstensen, Luis Rivera, Rasmus S Pedersen, Lourdes Peña, Klaus J Olsen, Lars V Andreasen, Ingrid Kromann, Pernille I Nielsen, Charlotte Sørensen, Jes Dietrich, Ananda S Bandyopadhyay, Birgit Thierry-Carstensen

Abstract

Background: Cost and supply constraints are key challenges in the use of inactivated polio vaccine (IPV). Dose reduction through adsorption to aluminium hydroxide (Al) is a promising option, and establishing its effectiveness in the target population is a crucial milestone in developing IPV-Al. The aim of this clinical trial was to show the non-inferiority of three IPV-Al vaccines to standard IPV.

Methods: In this phase 2, non-inferiority, observer-blinded, randomised, controlled, single-centre trial in the Dominican Republic, healthy infants aged 6 weeks, not previously polio vaccinated, were allocated after computer-generated randomisation by block-size of four, to receive one of four IPV formulations (three-times reduced dose [1/3 IPV-Al], five-times reduced dose [1/5 IPV-Al], ten-times reduced dose [1/10 IPV-Al], or IPV) intramuscularly in the thigh at 6, 10, and 14 weeks of age. The primary outcome was seroconversion for poliovirus types 1, 2, and 3 with titres more than or equal to four-fold higher than the estimated maternal antibody titre and more than or equal to 8 after three vaccinations. Non-inferiority was concluded if the lower two-sided 90% CI of the seroconversion rate difference between IPV-Al and IPV was greater than -10%. The safety analyses were based on the safety analysis set (randomly assigned participants who received at least one trial vaccination) and the immunogenicity analyses were based on the per-protocol population. This study is registered with ClinicalTrials.gov registration, number NCT02347423.

Findings: Between Feb 2, 2015, and Sept 26, 2015, we recruited 824 infants. The per-protocol population included 820 infants; 205 were randomly assigned to receive 1/3 IPV-Al, 205 to receive 1/5 IPV-Al, 204 to receive 1/10 IPV-Al, and 206 to receive IPV. The proportion of individuals meeting the primary endpoint of seroconversion for poliovirus types 1, 2, and 3 was already high for the three IPV-Al vaccines after two vaccinations, but was higher after three vaccinations (ie, after completion of the expanded programme of immunisation schedule): 1/3 IPV-Al 98·5% (n=202, type 1), 97·6% (n=200; type 2), and 99·5% (n=204, type 3); 1/5 IPV-Al: 99·5% (n=204, type 1), 96·1% (n=197, type 2), and 98·5% (n=202, type 3); and 1/10 IPV-Al: 98·5% (n=201, type 1), 94·6% (n=193, type 2), and 99·5% (n=203, type 3). All three IPV-Al were non-inferior to IPV, with absolute differences in percentage seroconversion for each poliovirus type being greater than -10% (1/3 IPV-Al type 1, -1·46 [-3·60 to 0·10], type 2, -0·98 [-3·62 to 1·49], and type 3, -0·49 [-2·16 to 0·86]; 1/5 IPV-Al type 1, -0·49 [-2·16 to 0·86], type 2, -2·45 [-5·47 to 0·27], and type 3, -1·46 [-3·60 to 0·10]; and 1/10 IPV-Al type 1, -1·47 [-3·62 to 0·10], type 2, -3·94 [-7·28 to -0·97], and type 3, -0·49 [-2·17 to 0·86]). Three serious adverse events occurred that were unrelated to the vaccine.

Interpretation: The lowest dose (1/10 IPV-Al) of the vaccine performed well both after two and three doses. Based on these results, this new vaccine is under investigation in phase 3 trials.

Funding: Bill & Melinda Gates Foundation.

Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure
Figure
Trial profile All vaccines were manufactured by SSI. FAS=full analysis set. IPV=inactivated polio vaccine. IPV-Al=IPV adsorbed to aluminium hydroxide. PP=per-protocol.

References

    1. WHO . Polio eradication & endgame strategic plan 2013–2018. World Health Organization; Geneva: 2013. (accessed March 22, 2017).
    1. Bandyopadhyay AS, Garon J, Seib K, Orenstein WA. Polio vaccination: past, present and future. Future Microbiol. 2015;10:791–808.
    1. Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. J Infect Dis. 2014;210(suppl 1):S459–S464.
    1. Sutter RW, John TJ, Jain H. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet. 2010;376:1682–1688.
    1. Sutter RW, Bahl S, Deshpande JM. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet. 2015;386:2413–2421.
    1. Saez-Llorens X, Clemens R, Leroux-Roels G. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016;16:321–330.
    1. Asturias EJ, Bandyopadhyay AS, Self S. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158–169.
    1. O'Ryan M, Bandyopadhyay AS, Villena R. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis. 2015;15:1273–1282.
    1. Estivariz CF, Pallansch MA, Anand A. Poliovirus vaccination options for achieving eradication and securing the endgame. Curr Opin Virol. 2013;3:309–315.
    1. Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012;16:e110–e116.
    1. Resik S, Tejeda A, Lago PM. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis. 2010;201:1344–1352.
    1. Resik S, Tejeda A, Sutter RW. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med. 2013;368:416–424.
    1. Mohammed AJ, AlAwaidy S, Bawikar S. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med. 2010;362:2351–2359.
    1. Resik S, Tejeda A, Mach O. Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity. Vaccine. 2015;33:5873–5877.
    1. Andreasen LV, Hansen LB, Andersen P, Agger EM, Dietrich J. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats. Vaccine. 2015;33:1873–1879.
    1. Lindgren LM, Tingskov PN, Justesen AH. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12 months and 5years of age. Vaccine. 2017;35:596–604.
    1. Vidor E, Plotkin SA. Poliovirus vaccine—inactivated. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 6th edn. Saunders; Philadelphia, PA: 2013. pp. 573–597.
    1. Melnick JL, Wenner HA, Phillips CA. Enteroviruses. In: Emmons RW, editor. Diagnostic procedures for viral, rickettsial and chlamydial infections. Washington, DC; American Public Health Association: 1976.
    1. Dayan GH, Thorley M, Yamamura Y. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis. 2007;195:12–20.
    1. Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Hum Vaccin Immunother. 2012;8:347–354.
    1. Plotkin SA, Liese J, Madhi SA, Ortiz E. A DTaP-IPV//PRP approximately T vaccine (Pentaxim): a review of 16 years' clinical experience. Expert Rev Vaccines. 2011;10:981–1005.
    1. Haastrup E, Thierry-Carstensen B, Jensen AM, Stellfeld M, Heilmann C. Safety and immunogenicity of a booster dose of inactivated poliovirus vaccine produced in vero-cells. Vaccine. 2004;22:958–962.
    1. Pietrzyk JJ, Wysocki J, Pejcz J. Safety and immunogenicity of a DTaP-IPV(Vero) (serum-free) combination vaccine in comparison to DTaP-IPV(Mkc) when administered simultaneously with Haemophilus influenzae type B conjugate vaccine (PRP-T) in children at 2, 3·5, 5 and 16 months of age. Vaccine. 2008;26:5296–5303.
    1. Thierry-Carstensen B, Dalby T, Stevner MA, Robbins JB, Schneerson R, Trollfors B. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults-A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience. Vaccine. 2013;31:5178–5191.
    1. Thierry-Carstensen B, Jordan K, Uhlving HH. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults. Vaccine. 2012;30:5464–5471.
    1. Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: a systematic review. Vaccine. 2012;30:6971–6979.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel